Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial
Raphael Schiffmann(Texas Christian University), Derralynn Hughes(Royal Free London NHS Foundation Trust), Martha R. Charney(Cytokinetics (United States)), Robert B. Colvin(Harvard University), Laura Barisoni(Duke University), Simeon A. Boyadjiev(University of California, Davis), Alona Paz(Protalix BioTherapeutics (Israel)), Kathy Nicholls(Melbourne Health), Özlem Göker-Alpan(Lysosomal and Rare Disorders Research and Treatment Center), Pilar Giraldo(Université Paris-Saclay), Mohamed G. Atta(Johns Hopkins University), Einat Brill‐Almon(Protalix BioTherapeutics (Israel)), Mali Szlaifer(Protalix BioTherapeutics (Israel)), Raul Chertkoff(Protalix BioTherapeutics (Israel)), Derlis Gonzalez(Instituto Privado de Hematología e Investigación Clínica), Charles J. Jennette(University of North Carolina at Chapel Hill), Sari Alon(Protalix BioTherapeutics (Israel)), Ahmad Tuffaha(University of Kansas Medical Center), Bonita Rup, Myrl Holida(University of Iowa), Gustavo Maegawa(Johns Hopkins Medicine)
Cited by 137
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
|Kidney International|1993|1.5k
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k